Hjälmås K, Hanson E, Hellström A L, Kruse S, Sillén U
Department of Paediatric Surgery, Sahlgrenska University Hospital/East, Göteborg, Sweden.
Br J Urol. 1998 Nov;82(5):704-9. doi: 10.1046/j.1464-410x.1998.00826.x.
To study the long-term efficacy and safety of desmopressin treatment in children with primary monosymptomatic nocturnal enuresis.
Children (aged 6-12 years) with nocturnal enuresis were recruited into an open multicentre trial. All children underwent an observation period of 4 weeks before starting a 6-week dose-titration period with desmopressin. If the number of wet nights decreased by more than half during medication, they began long-term treatment on 20-40 microg desmopressin. To test for cure and avoid overtreatment, the medication was interrupted for one week every third month.
Of the 399 children forming the intention-to-treat cohort, 245 halved their number of wet nights and started long-term treatment. During the periods off medication, 77 children were dry and at the end of the study another 73 (still on medication) reduced the number of wet nights to < or =10% of that during the observation period. A further 51 children halved the number of wet nights compared with the observation period. No serious adverse events occurred.
Long-term treatment with nasal desmopressin at a main dose of 40 microg is an effective and safe treatment for monosymptomatic nocturnal enuresis.
研究去氨加压素治疗原发性单症状性夜间遗尿症患儿的长期疗效和安全性。
招募夜间遗尿症患儿（6至12岁）参与一项开放性多中心试验。所有患儿在开始为期6周的去氨加压素剂量滴定期前，先经历4周的观察期。若用药期间尿床夜数减少超过一半，则开始使用20 - 40微克去氨加压素进行长期治疗。为检测治愈情况并避免过度治疗，每三个月停药一周。
在构成意向性治疗队列的399名儿童中，245名尿床夜数减半并开始长期治疗。在停药期间，77名儿童无尿床情况，在研究结束时，另有73名（仍在用药）儿童尿床夜数减少至观察期的≤10%。与观察期相比，另有51名儿童尿床夜数减半。未发生严重不良事件。
以40微克为主剂量的鼻用去氨加压素长期治疗是原发性单症状性夜间遗尿症的一种有效且安全的治疗方法。
